QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Difficult Risk Minimisation Measures and Adaptation

Test your understanding of the concepts covered by GVP Module XVI: Difficult Risk Minimisation Measures and Adaptation.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which situation best illustrates risk displacement?

A safety document is distributed later than planned A restriction reduces use of the product, but clinicians increasingly select an alternative with a different serious risk A healthcare professional recalls the message but does not change practice A patient receives a material in an inaccessible format

Question 2 of 10 Several marketing authorisation holders provide different safety instructions for products containing the same active substance. What is the principal regulatory and pharmacovigilance concern?

Consistency and coordinated implementation of the safety message may be compromised Product-specific requirements can never be maintained All products must use identical commercial packaging Coordination is unnecessary when the products have the same active substance

Question 3 of 10 An evaluation is conducted shortly after introduction of a measure intended to prevent an adverse outcome that develops only after many years of exposure. What is the principal limitation?

The evaluation can assess only regulatory approval status The timing may allow assessment of delivery and behaviour but not the ultimate clinical effect Long-latency risks cannot be evaluated at any stage Early implementation data are irrelevant to lifecycle management

Question 4 of 10 An educational material is scientifically accurate and reaches most intended prescribers, but the targeted prescribing practice changes very little. Which interpretation is most appropriate?

The primary weakness is likely inadequate distribution The measure may be failing at the transition from information to behaviour The clinical outcome has already demonstrated that the measure is ineffective The risk has necessarily been incorrectly characterised

Question 5 of 10 Which statement best reflects the MAH's responsibility when distribution and evaluation activities are performed by affiliates and vendors?

Responsibility transfers completely to the vendor performing the activity The MAH should retain sufficient oversight to understand whether the measure functions as intended The QPPV must personally perform every operational activity Only the local affiliate needs access to effectiveness findings

Question 6 of 10 When might withdrawal of an additional RMM be scientifically reasonable?

Whenever the measure creates any administrative burden When the underlying risk is no longer relevant or is adequately controlled by routine measures, supported by appropriate assessment Whenever distribution metrics are high As soon as one evaluation produces an uncertain result

Question 7 of 10 An approved RMM was scientifically reasonable, but one distributor failed to send required materials to a defined group of healthcare professionals. How should the issue initially be classified?

It is automatically proof that the RMM design was scientifically wrong It may represent an implementation or compliance failure requiring investigation and possibly CAPA It should be ignored if clinical outcomes remain stable It demonstrates that additional risk minimisation is no longer necessary

Question 8 of 10 A safety communication is consistently sent to prescribers, but the critical risk-control action is performed by laboratory personnel. Which principle has most likely been overlooked?

The need to use only routine risk minimisation measures The need to identify stakeholders according to who controls the critical behaviour The need to evaluate only clinical outcomes The need to avoid adapting measures to national healthcare systems

Question 9 of 10 Why is an objective such as 'increase awareness of the risk' generally insufficient for evaluating an RMM?

Awareness cannot be measured in pharmacovigilance It does not specify the relevant population, safety problem or expected behaviour or outcome It automatically requires a controlled clinical trial It focuses too heavily on clinical outcomes

Question 10 of 10 A company wants to replace a paper patient card with a mobile application. Which consideration is most consistent with the article's approach?

Digital delivery is automatically more effective than paper delivery The digital tool should be assessed against the same safety objective, including accessibility, reliability and workflow fit Digital tools eliminate the need for stakeholder engagement Data protection is unrelated to RMM effectiveness

Knowledge Assessment: Difficult Risk Minimisation Measures and Adaptation

Cookie Settings